Orion Group (ORN)
(Delayed Data from NYSE)
$8.65 USD
+0.04 (0.46%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $8.66 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ORN 8.65 +0.04(0.46%)
Will ORN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORN
Orion (ORN) Secures $63M Worth Contracts, Boosts Backlog
Why Orion Marine (ORN) Might be Well Poised for a Surge
ORN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Orion Marine (ORN) Maintain Its Recent Price Strength
Here is What to Know Beyond Why Orion Group Holdings, Inc. (ORN) is a Trending Stock
Is Orion Group (ORN) Stock Outpacing Its Construction Peers This Year?
Other News for ORN
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
Oryzon Genomics Shareholders Approve Capital Boost
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
Orion Minerals Pauses Trading Amid Capital Raise
Oryzon Genomics Finalizes Capital Increase